ATLAS Biolabs GmbH is a leading provider of complex analyses in molecular genetics including microarray-based genomic services, targeted sequence capture, and next-generation sequencing. ATLAS Biolabs performs genome-wide gene expression and SNP analyses, array CGH, comprehensive mutation profiling and next-generation sequencing for academic institutions, pharmaceutical and biotechnological enterprises, as well as for clinicians and registered doctors. Expert data processing and bioinformatics capabilities ensure a high added value to the data generated in its laboratories and highly flexible service options for different customer needs.
ATLAS Biolabs is a privately owned company (GmbH). It was founded by leading genome researchers from Germany as a spin-off from both the RZPD German Resource Center for Genome Research and the Cologne Center for Genomics (CCG). ATLAS Biolabs started its business operations in August 2007 in the centre of Berlin, Germany.
Prof. Dr. Peter Nürnberg, CEO, is an internationally renowned researcher in the field of human genetics and President of the German Association for Gene Diagnostics (AGD e.V.). He is full professor of genomics at the University of Cologne and - since 2005 - director of the Cologne Center for Genomics (CCG). From 2000 to 2004, he was head of the Gene Mapping Center (GMC) at the Max Delbrück Center (MDC) for Molecular Medicine, Berlin-Buch.
Dr. Karsten R. Heidtke, Director of Bioinformatics and Research, has long standing experience in leading IT and bioinformatics projects. Before joining ATLAS Biolabs in 2007, he was a Senior Scientist Bioinformatics at RZPD. He headed the Bioinformatics and IT group at the Biopsytec GmbH from 2000–2003 after completing his Ph.D. at the Max Planck Institute for Molecular Genetics.
Prof. Dr. Hans Lehrach is a director at the Max Planck Institute for Molecular Genetics in Berlin-Dahlem and an internationally renowned researcher in the field of vertebrate genomics. He was involved in the international Human Genome Project and has pioneered new applications of novel sequencing technologies.
Prof. Dr. Gundula Thiel is owner and head of a private practice for human genetics in Berlin. She is an expert in clinical genetics and molecular cytogenetics and teaches at the Charité in Berlin.
Dr. Roman Skoblo is founder, owner and CEO of IFLB Institute of Laboratory Diagnostics Berlin, a medical diagnostics laboratory in Berlin.